This study investigated the relationship between circulating total VEGF-A (tVEGF-A) and its isoforms with the therapeutic effects of anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody monotherapy in patients with non-small-cell lung cancer (NSCLC). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.